Jessica Fye
Stock Analyst at JP Morgan
(3.73)
# 790
Out of 4,641 analysts
166
Total ratings
55.45%
Success rate
5.69%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Maintains: Overweight | $180 → $174 | $127.41 | +36.57% | 7 | Oct 23, 2024 | |
| BGNE BeiGene | Maintains: Overweight | $200 → $235 | $220.11 | +6.76% | 4 | Oct 22, 2024 | |
| DNLI Denali Therapeutics | Maintains: Overweight | $29 → $28 | $25.90 | +8.11% | 4 | Oct 11, 2024 | |
| MBX MBX Biosciences | Initiates: Overweight | $30 | $23.40 | +28.21% | 1 | Oct 8, 2024 | |
| INSM Insmed | Maintains: Overweight | $72 → $74 | $71.96 | +2.83% | 5 | Oct 3, 2024 | |
| HALO Halozyme Therapeutics | Downgrades: Neutral | $52 → $57 | $50.97 | +11.83% | 11 | Sep 19, 2024 | |
| BNTX BioNTech SE | Upgrades: Neutral | $91 → $125 | $110.74 | +12.87% | 8 | Sep 16, 2024 | |
| MRNA Moderna | Downgrades: Underweight | $88 → $70 | $53.59 | +30.62% | 9 | Sep 13, 2024 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $111 → $120 | $69.60 | +72.40% | 2 | Sep 5, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $50 → $55 | $38.47 | +42.97% | 2 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $248 → $280 | $293.22 | -4.51% | 3 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $79 → $81 | $75.00 | +8.00% | 6 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $190 → $202 | $111.19 | +81.67% | 3 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $505 → $510 | $467.53 | +9.08% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $61 | $64.88 | -5.98% | 3 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $31 → $32 | $28.02 | +14.20% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $66 | $32.29 | +104.40% | 4 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $58.25 | -7.30% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $38.41 | +1.54% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $300 | $347.69 | -13.72% | 14 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $12.03 | +8.06% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $15.74 | +8.01% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $1.40 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.84 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $2.06 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $0.57 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $10 | $8.02 | +24.77% | 5 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $43.88 | +73.22% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $17 → $20 | $0.26 | +7,504.56% | 2 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.93 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $2.04 | +978.48% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.86 | +277.36% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $16.40 | +64.63% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.05 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $9.99 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.86 | - | 4 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $12.58 | - | 1 | Feb 8, 2018 |
Ascendis Pharma
Oct 23, 2024
Maintains: Overweight
Price Target: $180 → $174
Current: $127.41
Upside: +36.57%
BeiGene
Oct 22, 2024
Maintains: Overweight
Price Target: $200 → $235
Current: $220.11
Upside: +6.76%
Denali Therapeutics
Oct 11, 2024
Maintains: Overweight
Price Target: $29 → $28
Current: $25.90
Upside: +8.11%
MBX Biosciences
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $23.40
Upside: +28.21%
Insmed
Oct 3, 2024
Maintains: Overweight
Price Target: $72 → $74
Current: $71.96
Upside: +2.83%
Halozyme Therapeutics
Sep 19, 2024
Downgrades: Neutral
Price Target: $52 → $57
Current: $50.97
Upside: +11.83%
BioNTech SE
Sep 16, 2024
Upgrades: Neutral
Price Target: $91 → $125
Current: $110.74
Upside: +12.87%
Moderna
Sep 13, 2024
Downgrades: Underweight
Price Target: $88 → $70
Current: $53.59
Upside: +30.62%
BioMarin Pharmaceutical
Sep 5, 2024
Maintains: Overweight
Price Target: $111 → $120
Current: $69.60
Upside: +72.40%
Ionis Pharmaceuticals
Aug 26, 2024
Maintains: Neutral
Price Target: $50 → $55
Current: $38.47
Upside: +42.97%
Aug 26, 2024
Maintains: Neutral
Price Target: $248 → $280
Current: $293.22
Upside: -4.51%
Aug 21, 2024
Maintains: Overweight
Price Target: $79 → $81
Current: $75.00
Upside: +8.00%
Aug 19, 2024
Maintains: Overweight
Price Target: $190 → $202
Current: $111.19
Upside: +81.67%
Aug 5, 2024
Maintains: Overweight
Price Target: $505 → $510
Current: $467.53
Upside: +9.08%
Jul 31, 2024
Maintains: Neutral
Price Target: $59 → $61
Current: $64.88
Upside: -5.98%
Jul 25, 2024
Maintains: Neutral
Price Target: $31 → $32
Current: $28.02
Upside: +14.20%
Jul 10, 2024
Maintains: Overweight
Price Target: $70 → $66
Current: $32.29
Upside: +104.40%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $58.25
Upside: -7.30%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $38.41
Upside: +1.54%
May 21, 2024
Maintains: Overweight
Price Target: $280 → $300
Current: $347.69
Upside: -13.72%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $12.03
Upside: +8.06%
Mar 19, 2024
Maintains: Neutral
Price Target: $15 → $17
Current: $15.74
Upside: +8.01%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $1.40
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.84
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $2.06
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $0.57
Upside: -
Nov 20, 2023
Reinstates: Overweight
Price Target: $10
Current: $8.02
Upside: +24.77%
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $43.88
Upside: +73.22%
Mar 8, 2022
Upgrades: Overweight
Price Target: $17 → $20
Current: $0.26
Upside: +7,504.56%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $3.93
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $2.04
Upside: +978.48%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.86
Upside: +277.36%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $16.40
Upside: +64.63%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $2.05
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $9.99
Upside: -
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $0.86
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $12.58
Upside: -